APGE
Apogee Therapeutics, Inc.
$83.01
-4.50%
$6.4B
No data for this timeframe.
Vol
Market Cap$6.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders7 funds
Inst. Value$1.0B
Inst. Activity4 buys / 0 sells
Insider Activity0B / 14S
Insider Net $-$6.0M
SEC Reports11
Press Releases8
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001974640·Prev Close $86.92
Recent Activity
Jun 8, 2026
short_volume
Short Volume: APGE — 76.3% short (0.4M / 0.6M)
Short: 440,568 | Exempt: 0 | TRF Vol: 577,051 | Short Ratio: 76.3% | Off-exchange volume (dark pool
Jun 3, 2026
Insider
Dambkowski Carl sold 4,125 shares
Chief Medical Officer @ $0.00 ($0.00)
Jun 3, 2026
Insider
Dambkowski Carl sold 5,500 shares
Chief Medical Officer @ $78.71 ($432.9K)
Jun 3, 2026
Insider
Dambkowski Carl sold 4,125 shares
Chief Medical Officer @ $22.86 ($94.3K)
May 27, 2026
SEC
Apogee Therapeutics entered into a revenue participation agreement with Blackstone Life Sciences for up to $1.3 billion
8-K — Impact 7/10
May 27, 2026
SEC
Apogee Therapeutics announced positive 16-week induction dose optimization results from Part B of the Phase 2 APEX trial
8-K — Impact 7/10
May 16, 2026
SEC
CEO Michael Thomas Henderson sold $1.53M worth of APGE stock on May 13, 2026, and CMO Carl Dambkowski sold $311K on May
CLUSTER — Impact 3/10
Inst.
VANGUARD GROUP INC — ADD
2,857,824 shares ($215.7M)
Price Targets
$119.24
+40.3% upside
Strong Buy
Current $85.00
Low $81.00
Median $120.00
High $160.00
17 analysts
$81.00
$160.00
Analyst Ratings
10Strong Buy
10Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| May 27, 2026 | Truist Securities | MAINTAIN | Hold → Hold |
| May 27, 2026 | BTIG | REITERATE | Buy → Buy |
| May 27, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 1, 2026 | Rothschild & Co | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.89 ▲ +25.1% | $-1.25 — $0.31 | 22% YoY | 13 |
| Next Q | $-1.17 ▲ +4.9% | $-1.27 — $-0.93 | -5% YoY | 13 |
| Current FY | $-4.38 ▲ +9.1% | $-5.00 — $-3.25 | -4% YoY | 14 |
| Next FY | $-5.12 ▲ +5.7% | $-6.96 — $-4.12 | -17% YoY | 14 |
Latest Reports
BULLISH
8-K
7/10
Apogee Therapeutics entered into a revenue participation agreement with Blackstone Life Sciences for up to $1.3 billion
May 27, 2026
BULLISH
8-K
7/10
Apogee Therapeutics announced positive 16-week induction dose optimization results from Part B of the Phase 2 APEX trial
May 27, 2026
BULLISH
Press
7/10
Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion i
May 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $620.8M | — |
| VANGUARD GROUP INC | $215.7M | ADD |
| MORGAN STANLEY | $67.2M | ADD |
| BANK OF AMERICA CORP | $59.9M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $28.8M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Dambkowski Carl | M | $0.00 |
| Jun 3, 2026 | Dambkowski Carl | SELL | $432.9K |
| Jun 3, 2026 | Dambkowski Carl | M | $94.3K |
| May 13, 2026 | HENDERSON MICHAEL | SELL | $1.5M |
| May 6, 2026 | Dambkowski Carl | M | $0.00 |
7 institutional holders with $1.0B total value (13,295,923 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 8,225,038 | $620.8M | 61.9% | — |
| 2 | VANGUARD GROUP INC | 2,857,824 | $215.7M | 21.5% | ADD +27.3% |
| 3 | MORGAN STANLEY | 890,264 | $67.2M | 6.7% | ADD +91.5% |
| 4 | BANK OF AMERICA CORP /DE/ | 793,695 | $59.9M | 6.0% | DOUBLED +100.6% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 381,362 | $28.8M | 2.9% | NEW |
| 6 | TWO SIGMA INVESTMENTS, LP | 105,241 | $7.9M | 0.8% | TRIM -54.1% |
| 7 | WELLS FARGO & COMPANY/MN | 42,499 | $3.2M | 0.3% | ADD +93.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 2,245,631 | 2,857,824 | +27.3% | $215.7M | 2025-Q4 |
| MORGAN STANLEY | ADD | 464,963 | 890,264 | +91.5% | $67.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 395,612 | 793,695 | +100.6% | $59.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 21,990 | 42,499 | +93.3% | $3.2M | 2025-Q4 |
| UBS Group AG | DOUBLED | 107,157 | 799,465 | +646.1% | $31.8M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 16,853 | 21,990 | +30.5% | $873.7K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 41,100 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 252,135 | 115,694 | -54.1% | $5.0M | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 701,909 | 107,157 | -84.7% | $4.7M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 41,100 | — | $1.8M | 2025-Q2 |
| UBS Group AG | ADD | 541,286 | 701,909 | +29.7% | $26.2M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 209,534 | 519,939 | +148.1% | $19.4M | 2025-Q1 |
| UBS Group AG | DOUBLED | 51,820 | 541,286 | +944.6% | $24.5M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 8,800 | 78,424 | +791.2% | $3.6M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 98,290 | 17,705 | -82.0% | $802.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 280,428 | — | $16.5M | 2024-Q3 |
3 unique insiders with 14 transactions. Net insider value: -$6.0M ($0.00 bought, $6.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $0.00 | $0.00 |
| Jun 3, 2026 | Dambkowski Carl | Chief Medical Officer | SELL | 5,500 | $78.71 | $432.9K |
| Jun 3, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $22.86 | $94.3K |
| May 13, 2026 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | SELL | 18,659 | $82.05 | $1.5M |
| May 6, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $0.00 | $0.00 |
| May 6, 2026 | Dambkowski Carl | Chief Medical Officer | SELL | 3,700 | $83.92 | $310.5K |
| May 6, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $22.86 | $94.3K |
| May 1, 2026 | Henderson Jane | Chief Financial Officer | SELL | 811 | $81.02 | $65.7K |
| Apr 16, 2026 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | M | 3,000 | $22.86 | $68.6K |
| Apr 16, 2026 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | M | 3,000 | $0.00 | $0.00 |
| Apr 16, 2026 | Henderson Jane | Chief Financial Officer | SELL | 2,000 | $90.00 | $180.0K |
| Apr 8, 2026 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | SELL | 17,800 | $82.48 | $1.5M |
| Apr 1, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $0.00 | $0.00 |
| Apr 1, 2026 | Dambkowski Carl | Chief Medical Officer | SELL | 2,698 | $84.31 | $227.5K |
| Apr 1, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $22.86 | $94.3K |
| Apr 1, 2026 | Henderson Jane | Chief Financial Officer | SELL | 900 | $84.46 | $76.0K |
| Mar 25, 2026 | Henderson Jane | Chief Financial Officer | SELL | 2,000 | $85.00 | $170.0K |
| Mar 11, 2026 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | SELL | 8,363 | $74.29 | $621.3K |
| Mar 4, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $22.86 | $94.3K |
| Mar 4, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $0.00 | $0.00 |
| Mar 2, 2026 | Henderson Jane | Chief Financial Officer | SELL | 300 | $68.27 | $20.5K |
| Feb 11, 2026 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | SELL | 11,494 | $62.96 | $723.7K |
| Feb 4, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $22.86 | $94.3K |
| Feb 4, 2026 | Dambkowski Carl | Chief Medical Officer | SELL | 2,481 | $64.88 | $161.0K |
| Feb 4, 2026 | Dambkowski Carl | Chief Medical Officer | M | 4,125 | $0.00 | $0.00 |
| Feb 2, 2026 | Henderson Jane | Chief Financial Officer | SELL | 792 | $65.21 | $51.6K |
11 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 0 mixed, 6 neutral. Avg impact: 4.7/10.
BULLISH
8-K
7/10
Apogee Therapeutics entered into a revenue participation agreement with Blackstone Life Sciences for
May 27, 2026
BULLISH
8-K
7/10
Apogee Therapeutics announced positive 16-week induction dose optimization results from Part B of th
May 27, 2026
NEUTRAL
CLUSTER
3/10
CEO Michael Thomas Henderson sold $1.53M worth of APGE stock on May 13, 2026, and CMO Carl Dambkowsk
May 16, 2026
NEUTRAL
144
2/10
Director Michael Thomas Henderson filed a Form 144 on May 13, 2026, indicating intent to sell 60,000
May 13, 2026
BULLISH
8-K
7/10
Apogee Therapeutics reported Q1 2026 results with a net loss of $74.1M, wider than the $55.3M loss i
May 11, 2026
BULLISH
PRESS-RELEASE
7/10
Apogee Therapeutics reported Q1 2026 EPS of -$1.03, a 9% beat vs consensus of -$1.13, with no revenu
May 11, 2026
NEUTRAL
CLUSTER
2/10
Two C-suite insiders at Apogee Therapeutics sold a combined $377K in stock over a 7-day window, repr
May 9, 2026
NEUTRAL
DEFA14A
3/10
Apogee Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Cl
Apr 24, 2026
NEUTRAL
8-K
3/10
Apogee Therapeutics announced the resignation of two board members, Andrew Gottesdiener, M.D. and Pe
Apr 24, 2026
NEUTRAL
CLUSTER
4/10
Three corporate insiders at Apogee Therapeutics, including the CEO, CFO, and CMO, sold shares totali
Apr 11, 2026
BEARISH
CLUSTER
7/10
Two Apogee Therapeutics insiders — the CFO and CMO — sold a combined $303K in stock within a week of
Apr 4, 2026
BULLISH
7/10
Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences for
May 27, 2026
BULLISH
8/10
Apogee Therapeutics announced positive 16-week Phase 2 APEX Part B data for zumilokibart in moderate
May 27, 2026
NEUTRAL
6/10
Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zum
May 26, 2026
NEUTRAL
5/10
Apogee Therapeutics completed a public offering of 5,750,000 shares at $70.00 per share, raising app
Mar 26, 2026
BEARISH
6/10
Apogee Therapeutics priced an underwritten public offering of 5,000,000 shares at $70.00 per share,
Mar 25, 2026
BEARISH
7/10
Apogee Therapeutics (APGE) has announced a $300 million public offering of common stock, with an add
Mar 23, 2026
BULLISH
8/10
Apogee Therapeutics announced positive 52-week maintenance data from Part A of its Phase 2 APEX tria
Mar 23, 2026
NEUTRAL
5/10
Apogee Therapeutics reported full-year 2025 financial results with increased R&D and G&A spending dr
Mar 2, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 25 analysts: 10 strong buy, 10 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$119.24 mean target
+40.3% upside
Strong Buy (1.42)
$81.00 Low
$160.00 High
| Metric | Value |
|---|---|
| Current Price | $85.00 |
| Target Low | $81.00 |
| Target Mean | $119.24 |
| Target Median | $120.00 |
| Target High | $160.00 |
| # Analysts | 17 |
| Recommendation | Strong Buy (1.42) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.89 | $-1.25 | $0.31 | 21.6% | +25.1% | 12↑ 0↓ | $0.0B | 0.0% | 13 |
| Next Q 2026-09-30 |
$-1.17 | $-1.27 | $-0.93 | -5.1% | +4.9% | 10↑ 2↓ | $0.0B | 0.0% | 13 |
| Current FY 2026-12-31 |
$-4.38 | $-5.00 | $-3.25 | -3.7% | +9.1% | 12↑ 1↓ | $0.0B | 0.0% | 14 |
| Next FY 2027-12-31 |
$-5.12 | $-6.96 | $-4.12 | -16.9% | +5.7% | 9↑ 4↓ | $0.0B | 16.7% | 14 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.886 | |
| 7d ago | $-0.886 | |
| 30d ago | $-1.184 | +0.298 |
| 60d ago | $-1.182 | +0.296 |
| 90d ago | $-1.194 | +0.308 |
11 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| May 27, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| May 27, 2026 | BTIG | REITERATE | Buy | Buy |
| May 27, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 1, 2026 | Rothschild & Co | INITIATE | — | Buy |
| Mar 30, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 24, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 18, 2026 | Truist Securities | INITIATE | — | Hold |
| Mar 16, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 3, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Mar 3, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 22, 2026 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Jan 7, 2026 | Wolfe Research | INITIATE | — | Peer Perform |
| Jan 6, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Stephens & Co. | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 10 | 5 | 0 | 0 | 80% | |
| May 1, 2026 | 10 | 9 | 4 | 0 | 0 | 83% | |
| Apr 1, 2026 | 10 | 9 | 4 | 0 | 0 | 83% | |
| Mar 1, 2026 | 10 | 9 | 3 | 0 | 0 | 86% | |
| Feb 1, 2026 | 10 | 9 | 3 | 0 | 0 | 86% | |
| Jan 1, 2026 | 10 | 9 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
short_volume
Short Volume: APGE — 76.3% short (0.4M / 0.6M)
Short: 440,568 | Exempt: 0 | TRF Vol: 577,051 | Short Ratio: 76.3% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: APGE — 80.8% short (0.4M / 0.5M)
Short: 437,293 | Exempt: 244 | TRF Vol: 541,194 | Short Ratio: 80.8% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: APGE — 71.4% short (0.4M / 0.6M)
Short: 404,933 | Exempt: 3,404 | TRF Vol: 566,812 | Short Ratio: 71.4% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: APGE — 80.6% short (0.4M / 0.5M)
Short: 413,260 | Exempt: 2,388 | TRF Vol: 512,669 | Short Ratio: 80.6% | Off-exchange volume (dark pool + OTC)
May 28, 2026
other
Apogee Therapeutics to Participate in Upcoming June Conferences
<p align="justify">SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members
May 28, 2026
short_volume
Short Volume: APGE — 66.1% short (0.4M / 0.6M)
Short: 427,487 | Exempt: 0 | TRF Vol: 646,966 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
May 27, 2026
contract
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
<p align="center"><em>Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500
May 27, 2026
fda
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
<p align="center"><em>APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance
May 27, 2026
short_volume
Short Volume: APGE — 57.2% short (1.3M / 2.2M)
Short: 1,280,002 | Exempt: 0 | TRF Vol: 2,239,120 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 26, 2026
fda
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
Webcast to be held Wednesday, May 27th at 8:00 a.m. ET <pre>Webcast to be held Wednesday, May 27th at 8:00 a.m. ET</pre>
May 11, 2026
earnings
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
<p align="center"><em>Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:<
May 11, 2026
earnings_calendar
APGE Q1 2026 Earnings Scheduled — 2026-05-11
Apr 30, 2026
short_interest
FTD: APGE — 10,332 shares ($0.8M) failed to deliver
Settlement: 20260430, Price: $82.03, FTD Value: $847,533.96, APOGEE THERAPEUTICS INC COM
Apr 20, 2026
short_interest
FTD: APGE — 6,094 shares ($0.6M) failed to deliver
Settlement: 20260420, Price: $92.20, FTD Value: $561,866.8, APOGEE THERAPEUTICS INC COM
Apr 17, 2026
short_interest
FTD: APGE — 59,996 shares ($5.4M) failed to deliver
Settlement: 20260417, Price: $90.55, FTD Value: $5,432,637.8, APOGEE THERAPEUTICS INC COM